+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Plasma Protein Therapeutic Market Size, Share & Trends Analysis Report By Product (Albumin, Immunoglobulin, Factor VIII), By Application (Hemophilia, PID, ITP), By Region, And Segment Forecasts, 2018 - 2025

  • ID: 4751787
  • Report
  • December 2018
  • Region: Global
  • 86 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Biotest Ag.
  • Csl Behring Llc
  • Grifols
  • Kedrion S.P.A
  • Octapharma Ag
  • Shire Plc.
  • MORE
The global plasma protein therapeutics market size is expected to reach USD 33.15 billion by 2025. It is projected to register a CAGR of 4.8% over the forecast period. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.

Plasma-derived proteins are primarily used as replacement therapies to treat chronic, rare diseases. Patients that rely on these medications require regular injections or infusions throughout their lives. While there are more than 250 products derived from plasma, key players generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales and profitability.

Over the past decade, the plasma protein therapeutics market has grown lucratively with immunoglobulin capturing the major market share. Demand for plasma derived-products is driven by rising disease prevalence, geriatric population, and improved access to drugs in emerging markets. Approvals of new plasma-derived therapies are anticipated to further fuel the demand. Developing countries such as China and Brazil offer new investment avenues to the global market giants.

Further key findings from the report suggest:
  • Germany leads the European market, supported by high demand for blood components, presence of key players, large addressable population, and rising disease prevalence
  • Demand for immunoglobulin is expected to continue rising owing to prevalence of primary immunodeficiencies, usage in new indications, and ease of administration
  • Non-plasma based recombinant therapies are likely to compete with plasma-derived products in the factor VIII market
  • Asia Pacific is expected to exhibit high growth over the forecast period fuelled by increasing healthcare expenditure, presence of a large number patients. improved ratio of patients suffering from disease and patients receiving treatment, low-cost production of drugs, and improvement in diagnostic technology.
  • Major players operating in the plasma protein therapeutics market include CSL Behring, Grifols, S.A., Shire Plc, Octapharma AG, Biotest AG, and Kedrion S.P.A. Regional expansion, broad product portfolio, and merger & acquisitions are chief strategic undertakings adopted by key players.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biotest Ag.
  • Csl Behring Llc
  • Grifols
  • Kedrion S.P.A
  • Octapharma Ag
  • Shire Plc.
  • MORE
Chapter 1 Report Scope
1.1 Research Methodology
1.2 Market Scope
1.3 Regional Scope
1.4 Estimates And Forecasts Timeline

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Definitions

Chapter 4 Industry Outlook
4.1 Market Segmentation
4.2 Market Driver Analysis
4.2.1 Increase In Usage Of Plasma In Pharmaceutical Industry
4.2.2 Downstream Process Optimization
4.2.3 Increasing Geriatric Population
4.2.4 Expanding Applications
4.3 Market Restraint Analysis
4.3.1 Manufacturing And Storage Issues In Developing Regions
4.3.2 Slower Approval Procedures

Chapter 5 Competitive And Vendor Landscape
5.1 List Of Key Companies
5.2 List Of Strategic Initiatives
5.3 Company Market Share
5.4 Pipeline Analysis: Albumin, Phase III
5.5 Pipeline Analysis: Globulin, Phase III
5.6 Pipeline Analysis: Fibrinogen, Phase III

Chapter 6 Business Environmental Analysis
6.1 Business Environment Analysis Tools
6.1.1 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
6.1.2 Porter’s Five Forces Analysis

Chapter 7 Regulatory Outlook
7.1 Regulatory Landscape
7.1.1 U.S.
7.1.2 Canada
7.1.3 Up
7.1.4 Germany
7.1.5 Japan
7.1.6 China
7.1.7 Mexico
7.1.8 Brazil
7.1.9 Use
7.1.10 South Africa

Chapter 8 Product Business Analysis
8.1 Plasma Protein Therapeutics Market: Product Movement Analysis
8.2 Immunoglobulin
8.2.1 Immunoglobulin Market Estimates And Forecast, 2014 - 2025
8.3 Albumin
8.3.1 Albumin Market Estimates And Forecast, 2014 - 2025
8.4 Plasma Derived Factor Viii
8.4.1 Plasma Derived Factor Viii Market Estimates And Forecast, 2014 - 2025
8.5 Others
8.5.1 Others Market Estimates And Forecast, 2014 - 2025

Chapter 9 Application Business Analysis
9.1 Plasma Protein Therapeutics Market: Application Movement Analysis
9.2 Haemophilia
9.2.1 Haemophilia Market Estimates And Forecast, 2014 - 2025
9.3 Primary Immunodeficiencies
9.3.1 Primary Immunodeficiency Market Estimates And Forecast, 2014 - 2025
9.4 Idiopathic Thrombocytopenic Purpura
9.4.1 Idiopathic Thrombocytopenic Market Estimates And Forecast, 2014 - 2025
9.5 Others
9.5.1 Others Market Estimates And Forecast, 2014 - 2025

Chapter 10 Regional Business Analysis
10.1 Plasma Protein Therapeutics Market: Regional Movement Analysis
10.2 North America
10.2.1 North America Market Estimates And Forecast, 2014 - 2025
10.2.2 U.S.
10.2.2.1 U.S. Market Estimates And Forecast, 2014 - 2025
10.2.3 Canada
10.2.3.1 Canada Market Estimates And Forecast, 2014 - 2025
10.3 Europe
10.3.1 Europe Market Estimates And Forecast, 2014 - 2025
10.3.2 Germany
10.3.2.1 Germany Market Estimates And Forecast, 2014 - 2025
10.3.3 Up
10.3.3.1 Up Market Estimates And Forecast, 2014 - 2025
10.4 Asia-Pacific
10.4.1 Asia-Pacific Market Estimates And Forecast, 2014 - 2025
10.4.2 China
10.4.2.1 China Market Estimates And Forecast, 2014 - 2025
10.4.3 India
10.4.3.1 India Market Estimates And Forecast, 2014 - 2025
10.5 Latin-America
10.5.1 Latin America Market Estimates And Forecast, 2014 - 2025
10.5.2 Brazil
10.5.2.1 Brazil Market Estimates And Forecast, 2014 - 2025
10.5.3 Mexico
10.5.3.1 Mexico Market Estimates And Forecast, 2014 - 2025
10.6 Middle East & Africa
10.6.1 Middle-East And Africa Market Estimates And Forecast, 2014 - 2025
10.6.2 South Africa
10.6.2.1 South Africa Market Estimates And Forecast, 2014 - 2025

Chapter 11 Company Profile
11.1 Csl Behring Llc
11.1.1 Company Overview
11.1.2 Financial Performance
11.1.3 Product Benchmarking
11.1.4 Strategic Initiatives
11.2 Grifols
11.2.1 Company Overview
11.2.2 Financial Performance
11.2.3 Product Benchmarking
11.2.4 Strategic Initiatives
11.3 Shire Plc.
11.3.1 Company Overview
11.3.2 Financial Performance
11.3.2.1 Product Benchmarking
11.3.2.2 Strategic Initiatives
11.4 Octapharma Ag
11.4.1 Company Overview
11.4.2 Financial Performance
11.4.2.1 Product Benchmarking
11.4.2.2 Strategic Initiatives
11.5 Biotest Ag.
11.5.1 Company Overview
11.5.2 Financial Performance
11.5.2.1 Product Benchmarking
11.5.2.2 Strategic Initiatives
11.6 Kedrion S.P.A
11.6.1 Company Overview
11.6.2 Financial Performance
11.6.2.1 Product Benchmarking
11.6.2.2 Strategic Initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Csl Behring Llc
  • Grifols
  • Shire Plc.
  • Octapharma Ag
  • Biotest Ag.
  • Kedrion S.P.A
Note: Product cover images may vary from those shown
Adroll
adroll